Treatment of Localized (Unicentric) Castleman Disease

Surgery is the recommended treatment for people with localized Castleman disease (CD) whenever possible. Removing the abnormal lymph node(s) usually cures the disease. Symptoms such as fever and fatigue that are caused by the CD go away when the lymph node is removed. Relapses are rare.

Sometimes if the diseased area is too large to be removed by surgery, medicines such as corticosteroids or rituximab might be given first. This can shrink the tumor and make it easier to remove.

Radiation can also be used to treat localized CD, either in people who can’t have surgery for some reason or if surgery cannot remove all of the disease. But radiation is not used as often as surgery as the main treatment.

Some patients with localized CD develop secondary amyloidosis, a condition in which abnormal proteins build up in the kidneys, skin, and some other organs. This protein build-up stops once the lymph node(s) affected by CD is removed.

The outlook for localized CD is very good if the affected lymph node(s) can be removed with surgery (or treated with radiation). But sometimes not all of the disease can be removed or treated safely. This doesn’t necessarily mean it will continue to grow and get worse. Even partial removal may help, and the disease may not grow back.

The American Cancer Society medical and editorial content team
Our team is made up of doctors and master's-prepared nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.

Gross TG. Immunodeficiency and cancer. In: Neiderhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, PA. Elsevier; 2014:1991-2017.

Munshi NC, Jaggannath S. Plasma cell neoplasms. In: Hematology: Basic Principles and Practice, 7th ed. Hoffman R, Benz Jr. E, Silberstein LE, Heslop H, Weitz JI, Anastasi J, Salama ME, Abutalib SA, eds. Philadelphia, PA. Elsevier; 2018: 1381-1418. 

Nagubandi R, Wang Y, Dutcher JP, Rao PM. Classic case of unicentric mixed-type Castleman’s disease. J Clin Oncol. 2013;31:e452–455

National Cancer Institute. Physician Data Query (PDQ). AIDS-related lymphoma treatment. 10/02/2015. Accessed at: https://www.cancer.gov/types/adrenocortical/hp/adrenocortical-treatment-pdq  on January 11, 2018.

National Cancer Institute. Castleman disease. Accessed at https://seer.cancer.gov/seertools/hemelymph/532b3e3fe4b0626b1926ec92/ on January 10, 2018.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: B-cell lymphomas. v.7.2017. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf  on January 11, 2018 . 

National Organization for Rare Disorders. Castleman disease. Accessed at https://rarediseases.org/rare-diseases/castlemans-disease/ on January 5, 2018.

Rajkumar SV, Dispenzieri A. Multiple myeloma and related disorders In: Neiderhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, PA. Elsevier; 2014:1991-2017.

Sarana B, Jaal J, Tamm H, Laisaar T. Resection of unicentric interlobar Castleman disease with following adjuvant radiotherapy. SAGE Open Med Case Rep. 2017;5:2050313X17744481.

Wong RSM. Unicentric Castleman disease. Hematol Oncol Clin North Am. 2018;32(1):65-73.

Yarchoan R, Uldrick TS, Polizzotto MN, Little RF. HIV-associated malignancies. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2015:1780-1792.

Last Medical Review: January 12, 2017 Last Revised: February 5, 2018

American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.